A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm, Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson’s Disease-Associated Apathy, Motor Symptoms, and Mood ("BRIGHT")

ID Number 13-0394

Principal Investigator(s)
Winona Tse

Department(s) or Division(s)


Patients with Parkinson's disease have low levels of dopamine in the brain. Rotigotine, the drug being studied, acts like dopamine and may relieve some symptoms of Parkinson's disease. It is given in the form of a patch worn 24 hours on the skin. The primary purpose of this study is to see if rotigotine works better than placebo (no active drug) in improving the motor skills and the symptoms of mood and apathy that are part of Parkinson's disease.

Contact Information
Joan Bratton
(212) 241-0279
Amber Servi
(212) 241-2477

Recruiting Patients: Yes